S&P 500
7,516.60
+0.45%
Dow Jones
52,923.60
+0.01%
Nasdaq 100
29,706.80
+1.19%
Russell 2000
3,007.21
+0.49%
FTSE 100
10,654.20
-0.33%
Nikkei 225
69,824.80
+2.22%

Health and Healthcare

Another Bump Up for Dendreon and PROVENGE (DNDN)

Photo of Jon C. Ogg
By Jon C. Ogg Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted that this new coverage of PROVENGE is now consistent with all other infused biologics.

The costs associated with administering PROVENGE will now be covered and can be billed separately. More importantly, the CMS decision will retroactively cover claims for costs associated with the administration of PROVENGE effective for dates on or after June 30, 2011.  This now takes the average time to pay physicians to 30 days according to the company.

Dendreon shares are up over 8% at $9.03 in pre-market trading with about 55 minutes until the market opens and the 52-week trading range is $6.46 to $43.96.

JON C. OGG

Contact [email protected] for any questions or corrections.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

HYSA or Treasury Bills for Your Emergency Fund
Austin Smith |

HYSA or Treasury Bills for Your Emergency Fund
SPYM vs VTI: Which Trump Account ETF Actually Builds More Wealth by Age 18
Michael Williams |

SPYM vs VTI: Which Trump Account ETF Actually Builds More Wealth by Age 18

Continue Reading

David J. Phillips |

Dendreon: Not Running Out Of Cash

In the last four months, Dendreon Corp. (DNDN) has shed almost 84 percent in market value as disgruntled investors washed…

Jon C. Ogg |

The Questionable Dendreon Buyout Incentive

Dendreon Corp. (NASDAQ: DNDN) is by almost all measurements nothing short of a total failure of a biotech or biohealth…

Jon C. Ogg |

Dendreon Shows Poor Provenge Sales, Implosion Risk Rising

ThinkstockDendreon Corp. (NASDAQ: DNDN) just cannot catch a break. Despite having what was supposed to be one of the best…

Douglas A. McIntyre |

Will The E.U. Save Dendreon If The U.S. Won’t? (DNDN)

Dendreon Corp. (NASDAQ:DNDN) shares are trading up in early trading on a patent award, and that is after the fairly…

Jon C. Ogg |

Will the Last Interested Person in Dendreon Turn Out the Lights?

Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported…

Douglas A. McIntyre |

Dendreon’s New Double-Twist

Dendreon (DNDN-NASDAQ) has an interesting twist this morning because of two issues.  Yesterday it announced some new study data on…

Jon C. Ogg |

Dendreon Restructuring Aims to Thwart Weak Provenge Sales

ThinkstockDendreon Corp. (NASDAQ: DNDN) has been down and out, and now the company is going to try a restructuring strategy…

Jon C. Ogg |

Picking Apart the Dendreon Implosion (DNDN)

Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for…

Jon C. Ogg |

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales…

Top Gaining Stocks

Genuine Parts
GPC • Vol: 5,088,383
Moderna
MRNA • Vol: 14,112,476
Equifax
EFX • Vol: 2,195,638
Vertex Pharmaceuticals
VRTX • Vol: 1,879,133
S&P Global
SPGI • Vol: 3,749,613

Top Losing Stocks

Teradyne
TER • Vol: 5,938,036
KLA
KLAC • Vol: 23,648,857
Corning
GLW • Vol: 21,192,211
Seagate Technology
STX • Vol: 6,302,838
Lam Research
LRCX • Vol: 18,973,383